AU2004305582A1 - Composition and methods for modulating CNS activity - Google Patents

Composition and methods for modulating CNS activity Download PDF

Info

Publication number
AU2004305582A1
AU2004305582A1 AU2004305582A AU2004305582A AU2004305582A1 AU 2004305582 A1 AU2004305582 A1 AU 2004305582A1 AU 2004305582 A AU2004305582 A AU 2004305582A AU 2004305582 A AU2004305582 A AU 2004305582A AU 2004305582 A1 AU2004305582 A1 AU 2004305582A1
Authority
AU
Australia
Prior art keywords
agonist
certain embodiments
mammal
pct
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004305582A
Other languages
English (en)
Inventor
Lee L. Rubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curis Inc
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of AU2004305582A1 publication Critical patent/AU2004305582A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2004305582A 2003-12-19 2004-12-15 Composition and methods for modulating CNS activity Abandoned AU2004305582A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53120103P 2003-12-19 2003-12-19
US60/531,201 2003-12-19
PCT/US2004/042271 WO2005061002A2 (en) 2003-12-19 2004-12-15 Composition and methods for modulating cns activity

Publications (1)

Publication Number Publication Date
AU2004305582A1 true AU2004305582A1 (en) 2005-07-07

Family

ID=34710209

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004305582A Abandoned AU2004305582A1 (en) 2003-12-19 2004-12-15 Composition and methods for modulating CNS activity

Country Status (9)

Country Link
US (1) US20050203014A1 (enExample)
EP (1) EP1694353A2 (enExample)
JP (1) JP2007521333A (enExample)
CN (1) CN1917897A (enExample)
AU (1) AU2004305582A1 (enExample)
BR (1) BRPI0417491A (enExample)
CA (1) CA2547338A1 (enExample)
MX (1) MXPA06006659A (enExample)
WO (1) WO2005061002A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224302A1 (en) * 2002-07-16 2004-11-11 Thomas Jessel Systems and methods for screening for modulators of neural differentiation
US7632679B2 (en) * 2002-07-16 2009-12-15 The Trustees Of Columbia University In The City Of New York Systems and methods for screening for modulators of neural differentiation
US7390659B2 (en) 2002-07-16 2008-06-24 The Trustees Of Columbia University In The City Of New York Methods for inducing differentiation of embryonic stem cells and uses thereof
WO2007028770A1 (en) * 2005-09-05 2007-03-15 Neurosearch A/S Monoamine neurotransmitter re-uptake inhibitors for neuroprotection in patients suffering from an advanced stage of a mental disease
JP2009521403A (ja) * 2005-11-14 2009-06-04 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Ｍｒｉによる神経発生の相関の画像法
WO2008127974A1 (en) * 2007-04-13 2008-10-23 The Trustees Of Columbia University In The City Of New York Stem cell-based culture system for drug development
US8969081B2 (en) * 2008-12-10 2015-03-03 The Trustees Of Columbia University In The City Of New York Caudal motor neuron derived from embryonic stem cells under conditions essentially free of any retinoid
FR2966733B1 (fr) * 2010-10-29 2012-12-14 Centre Nat Rech Scient Nouvelles strategies therapeutiques impliquant la voie de signalisation hedgehog
CN104740633A (zh) * 2013-12-26 2015-07-01 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
JP6193176B2 (ja) * 2014-05-12 2017-09-06 ライオン株式会社 活力及び／又は集中力向上剤
CN111551729B (zh) * 2020-04-27 2021-02-09 浙江正熙生物技术股份有限公司 藻红蛋白免疫荧光探针制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610656B1 (en) * 1993-12-30 2003-08-26 President And Fellows Of Harvard College Method of promoting chondrocyte differentiation with hedgehog related polypeptides
US5789543A (en) * 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
US6261786B1 (en) * 1993-12-30 2001-07-17 Imperial Cancer Res. Technology Screening assays for hedgehog agonists and antagonists
US6165747A (en) * 1993-12-30 2000-12-26 President & Fellows Of Harvard College Nucleic acids encoding hedgehog proteins
US6384192B1 (en) * 1993-12-30 2002-05-07 President & Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins
EP1616942A3 (en) * 1994-10-07 2006-11-22 The Board Of Trustees Of The Leland Stanford Junior University Patched genes and their use
US6027882A (en) * 1994-10-07 2000-02-22 The Regents Of The University Of California Patched genes and their use for diagnostics
US6429354B1 (en) * 1994-10-07 2002-08-06 The Board Of Trustees Of The Leland Stanford Junior University Patched genes and uses related thereto
US7144997B2 (en) * 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
US6897297B1 (en) * 1997-12-03 2005-05-24 Curis, Inc. Hydrophobically-modified protein compositions and methods
WO2000035948A1 (en) * 1998-12-03 2000-06-22 Biogen, Inc. Methods and compositions for treating disorders involving excitotoxicity
EP1743903A2 (en) * 1998-12-03 2007-01-17 Curis, Inc. Methods and compositions for treating disorders involving excitotoxicity
US20030165897A1 (en) * 1999-12-21 2003-09-04 Burke Richard E. Dispatched polypeptides
US6683192B2 (en) * 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2001082946A2 (en) * 2000-04-28 2001-11-08 Curis, Inc. Neuroprotective compositions
JP2004518654A (ja) * 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US20060078499A1 (en) * 2003-12-01 2006-04-13 Rene Hen Use of hedgehog agonist to treat depression

Also Published As

Publication number Publication date
CA2547338A1 (en) 2005-07-07
WO2005061002A3 (en) 2005-09-29
WO2005061002A2 (en) 2005-07-07
CN1917897A (zh) 2007-02-21
US20050203014A1 (en) 2005-09-15
MXPA06006659A (es) 2006-08-31
EP1694353A2 (en) 2006-08-30
BRPI0417491A (pt) 2007-05-22
JP2007521333A (ja) 2007-08-02

Similar Documents

Publication Publication Date Title
ES2329635T3 (es) Secuencias de nucleotidos y proteinas de los genes nogo y metodos basados en estas.
JP2024069452A (ja) ドライアイの治療用医薬組成物
KR101953736B1 (ko) 제브라피시 모델을 사용한 약물 스크리닝 방법 및 이 방법으로 스크린된 화합물
Mwaikambo et al. Activation of CD36 inhibits and induces regression of inflammatory corneal neovascularization
KR20140120926A (ko) p75NTR 뉴로트로핀 결합 단백질의 치료학적 용도
JP2010528016A (ja) 細胞を刺激するための方法および組成物
AU2009214625A1 (en) Combination of alpha 7 nicotinic agonists and antipsychotics
KR20070026650A (ko) 케르베루스/코코 유도체 및 그의 용도
Ferent et al. Hedgehog: multiple paths for multiple roles in shaping the brain and spinal cord
US20050203014A1 (en) Composition and methods for modulating CNS activity
JP2020513005A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
Cao et al. Expression of nerve growth factor carried by pseudotyped lentivirus improves neuron survival and cognitive functional recovery of post‐ischemia in rats
EP2968452A1 (en) Compositions and methods for treating retinal disease
Tu et al. Notch1 signaling activation contributes to adult hippocampal neurogenesis following traumatic brain injury
WO2002059155A2 (en) Modulation of calcium channel activity
Chagraoui et al. 5-HT6 receptors: Contemporary views on their neurobiological and pharmacological relevance in neuropsychiatric disorders
Emek et al. Pridopidine, a potent and selective therapeutic sigma-1 receptor (S1R) agonist for treating neurodegenerative diseases
WO2016125330A1 (ja) 網膜再生促進薬
Bitzer et al. Effects of muscarinic antagonists on ZENK expression in the chicken retina
US11097005B2 (en) Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
US20130209476A1 (en) Treatment of inflammatory disorders
KR101585794B1 (ko) miRNA를 이용한 안과 질환의 예방 또는 치료
CN109069477A (zh) 用于利用促蠕动蛋白2激动剂和拮抗剂来治疗昼夜节律紊乱的组合物和方法
Dailey et al. A recombinant norrin-derived growth factor retains the complete multifunctionality of human norrin
Jenck et al. Brain 5-HT2Creceptors: potential role in anxiety disorders

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application